Who We Are

Ubuntu Research Inc. was formed with a mission to bring highly innovative therapies to patients in an expedient, sustainable and contemporaneous fashion.

Our goal

Our goal is to serve patient communities by partnering with emerging biotech organizations that are focused in the development of cellular and gene transfer therapeutics. Dimension-T^™ , is a subscription oriented services platform that offers bespoke solution for young biotechnology companies to conceive and create robust clinical development strategies, efficient resource plans and generate core capabilities required to accelerate clinical development. We aspire to translate the benefits of optimised risk, cost and time of drug development into better and more meaningful outcomes for patients.

Our purpose

Our purpose is to bring modern age medical innovations to patients in a faster, competent and reliable manner. We have identified untapped and significant value in how biotechnology companies today are formed (under the auspices of a vested group of investors, e.g. Focused Biotech Investment funds), capitalized/ organized and the manner in which they execute clinical programs. By adopting a novel, value oriented approach; we seek to gain marked time (and cost) efficiencies, reduce uncertainty and minimize developmental risks across all Phases of clinical execution. Successful implementation of our solution will result in faster, reliable and higher quality business milestones (e.g. time to IND, Clinical PoC, BLA). In parallel it will build on and harness the knowledge/ learnings assimilated through the process; allowing for it to pollinate across the “vested group/ venture fund” ecosystem.

Our Dimension-T^™ solution

Our Dimension-T^™ solution is an agile, sustainable, scalable and efficient clinical development operations framework. It is developed on the premise of a shared infrastructure of on demand/ subscription oriented solutions enabling clinical trial process & customized clinical trials technology platform(s). This would in turn result in rapid & efficient set-up of clinical trials and yield high quality execution of clinical stage assets (i.e. drugs). This in turn allows for the companies to focus their valuable resources on novel technologies, market leadership strategies and other contemporaneous business solutions.